Trial Profile
Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (rituximab by Hoffman-La Roche) in Patients with Diffuse Large B-cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 May 2019
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Pharmacokinetics; Registrational
- Acronyms MADILYM
- Sponsors Mabion
- 26 May 2019 Trial has been completed in Croatia.
- 12 Mar 2018 This trial has been completed in Poland (End date: 2018-01-04).
- 12 Nov 2014 New trial record